Author:
Brindha A.,Sunitha Karnam Anantha,Venkatraman B.,Menaka M.,Arjunan Sridhar P.
Reference114 articles.
1. Maiti, P., Manna, J., Dunbar, G.L.: Current understanding of the molecular mechanisms in Parkinson’s disease: Targets for potential treatments. Transl. Neurodegener. 6, 28 (2017)
2. Ibrahim, N., Kusmirek, J., Struck, A.F., Floberg, J.M., Perlman, S.B., Gallagher, C., Hall, L.T.: The sensitivity and specificity of F-DOPA PET in a movement disorder clinic. Am. J. Nucl. Med. Molec. Imag. 6(1), 102 (2016)
3. Jankovic, J., Tan, E.K.: Parkinson’s disease: etiopathogenesis and treatment. J. Neurol. Neuros. Psyc. 91(8), 795–808 (2020)
4. Hong, Z., Shi, M., Chung, K.A., Quinn, J.F., Peskind, E.R., Galasko, D., … Zhang, J.: DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133(3), 713 − 726 (2010)
5. Longhena, F., Faustini, G., Missale, C., Pizzi, M., Spano, P., Bellucci, A.: The contribution of α-synuclein spreading to Parkinson’s disease synaptopathy. Neur. Plast. (2017)